Theravance Biopharma Inc

NASDAQ:TBPH   3:59:57 PM EDT
17.99
-0.03 (-0.17%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.15B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$20.2 Million
Adjusted EPS-$1.04
See more estimates
10-Day MA$17.58
50-Day MA$17.83
200-Day MA$20.59
See more pivots

Theravance Biopharma, Inc. Stock, NASDAQ:TBPH

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, CAYMAN ISLANDS KY1-1104
Cayman Islands
Phone: 650-808-6000
Number of Employees: 363

Description

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The company's product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.